They enter into exclusive negotiations in a new drive to create a technology-driven leader for complex small molecules and ADCs of global scale
_256_384.jpg)
CLSA, a capital market and investment group organised an Investors’ Forum where five Indian pharma companies participated. Excerpts from the report
Between 30-40 per cent of Covid-19 patients are either obese or diabetic
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Domestic business was up 41.9% YoY and 27.7% QoQ
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
Anti-malaria API facility will be operational in 15-18 months
Subscribe To Our Newsletter & Stay Updated
